The Therapeutic Goods Administration (TGA), in conjunction with Sandoz Pty Ltd and Novartis Australia, has investigated reports of counterfeit Somatropin HGH vials in community circulation.
From this investigation the TGA has established that Novartis-Bio Somatropin HGH (191 amino acid sequence rDNA origin for injection) 3.7mg per Vial (10x10IU Vials of Somatropin) as presented in the photographs below is not marketed in Australia by either Sandoz Pty Ltd or Novartis Australia.
The manufacturer of the original product, Novartis-Bio, confirmed that the product in question is not a commercial product of Novartis Australia and is a suspected counterfeit based on the packaging and invalid batch number present on the product.
Leave a Reply